Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07197645 · ClinicalTrials.gov registry record · Phase 1
Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
A Phase 1 study of Bone Pain and Metastatic Bone Tumor, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 3
- Study locations
NCT07197645 is a Phase 1 study of Bone Pain and Metastatic Bone Tumor that is actively recruiting participants, run by Telix Pharmaceuticals (Innovations) Pty Limited. The registered enrollment target is 33 participants. The trial reports 3 study locations across 1 state.
The verdict
NCT07197645, a Phase 1 study of Bone Pain and Metastatic Bone Tumor, is actively recruiting participants, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.
Conditions Studied
Interventions
- DRUG 153Sm-DOTMP
Study Locations (3)
Texas
- Houston Metro Urology - Houston
- Oncology Consultants - Houston
- Excel Diagnostics and Nuclear Oncology Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2025-10-21 |
| Est. Completion | 2027-07-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07197645
The ClinicalTrials.gov registry entry for NCT07197645 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telix Pharmaceuticals (Innovations) Pty Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Bone Pain appearing as the primary indexed condition, and to 1 intervention - of which 153Sm-DOTMP is the first listed.
NCT07197645 reports 3 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07197645 about?
NCT07197645 is a clinical study titled "Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain". This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.
What is the current status of trial NCT07197645?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2025-10-21. Estimated completion is 2027-07-05.
What conditions does trial NCT07197645 study?
This clinical trial studies the following conditions: Bone Pain, Metastatic Bone Tumor, Bone Metastases in Subjects With Advanced Cancer.
What interventions are being tested in trial NCT07197645?
The interventions under investigation include: 153Sm-DOTMP (DRUG).
Who is sponsoring clinical trial NCT07197645?
This trial is sponsored by Telix Pharmaceuticals (Innovations) Pty Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07197645 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bone Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.